A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections

D Matthew Shoemaker
Jikerkhoun Simou
William E Roland

Division of Infectious Diseases, University of Missouri Hospital, Columbia, MO, USA

Abstract: Daptomycin is a novel bactericidal antibiotic with excellent activity against gram-positive organisms. It is a large cyclic lipopeptide with a unique mechanism of action. Daptomycin is given once a day and is renally cleared, requiring dose adjustment in patients with impaired renal function. Unfortunately, there have been case reports of resistant gram-positive organisms. Daptomycin is generally well tolerated, though myopathy has been reported. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors should be stopped in patients on daptomycin. Daptomycin shows promise in experimental models of endocarditis, meningitis, ventriculitis, and peritonitis, and is currently approved for use in skin and soft-tissue infections. Daptomycin is a welcome newcomer to the gram-positive antimicrobial arsenal.

Keywords: daptomycin, lipopeptide, antibiotic, skin infection

Introduction

With the increasing numbers and types of resistant organisms, there is an increasing need for antibiotics to treat infections caused by them. Daptomycin is a cyclic lipopeptide with a broad spectrum of activity against gram-positive organisms, both aerobic and anaerobic. This includes resistant strains as well such as methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate Staphylococcus aureus (GISA), vancomycin-resistant enterococci (VRE), coagulase-negative staphylococci (CoNS), and penicillin-resistant Streptococcus pneumoniae (PRSP).

Daptomycin was discovered in the early 1980s, at Eli Lilly and Company (Tally and DeBruin 2000). Daptomycin was initially developed in the late 1980s and early 1990s but was ultimately shelved due to concerns regarding adverse effects, in particular drug-induced myopathy. Cubist Pharmaceuticals Inc. licensed worldwide rights from Eli Lilly and Company in 1997 (Tally and DeBruin 2000).

Basics/mechanism of action

Daptomycin is derived as a fermentation product from Streptomyces roseospours. The unique structure of daptomycin consists of a 13-member amino acid cyclic lipopeptide with a decanoyl side-chain (Steenbergen et al 2005) (Figure 1). Daptomycin molecular weight is 1620.67 (Cubicin package insert 2003). This is a rather large molecule which may influence its distribution into tissues.

The exact details of daptomycin’s mechanism of action are not completely understood. It is believed to have a unique mechanism of action that involves calcium-dependent insertion of the lipophilic daptomycin tail into the bacterial cell membrane,
causing rapid depolarization and potassium ion efflux (Steenbergen et al 2005) (Figure 2). It has been observed that daptomycin causes a calcium-dependent dissipation of the membrane potential (Δψ) in *Staphylococcus aureus* without noticeably affecting the chemical gradient (ΔpH) across the membrane (Alborn et al 1991). This unique mechanism of action makes daptomycin rapidly bactericidal.

**Pharmacokinetics**

Daptomycin exhibits linear pharmacokinetics across a wide range of doses with once daily dosing up to 6 mg/kg (Figure 3) (Woodworth et al 1992; Dvorchik et al 2003). Daptomycin doses of 8 mg/kg exhibit a slight nonlinearity (Dvorchik et al 2003).

Approximately 92% of daptomycin is protein-bound (Woodworth et al 1992). Excretion of the drug occurs primarily via the kidney with approximately 80% of the total dose, of which two-thirds is intact drug, recovered in the urine (Tally and DeBruin 2000). Due to daptomycin’s predominant renal clearance, it requires dose adjustments in those with impaired renal function. Daptomycin clearance in females is estimated to be approximately 80% that of males with similar renal function, although this has otherwise not been shown to be statistically or clinically significant (Dvorchik et al 2004).

The observed t½ is relatively long (~9 hours) (Dvorchik et al 2003). The long t½ allows for once daily dosing in patients with normal renal function. Daptomycin t½ is increased by 2.3-fold in patients with creatinine clearance (CLcr) <40 mL/min and 3.5-fold in patients on dialysis (Dvorchik et al 2004).

Daptomycin remains in the plasma and interstitial fluid and therefore has a small volume of distribution (Dvorchik et al 2003, 2004).

The maximum serum concentration after escalating single daily doses of daptomycin ranged from approximately 55, 85 to 95 µg/mL, and 115 to 130 µg/mL with doses of 4, 6, and 8 mg/kg, respectively (Dvorchik et al 2003). The area under the curve following doses of 4, 6, and 8 mg/kg/day revealed similar linearity to the Cmax pharmacokinetic data above (Dvorchik et al 2003, 2004).

Daptomycin has been shown to exhibit a post-antibiotic effect (PAE) on *Staphylococcus aureus* and *Streptococcus pneumoniae* (Pankuck et al 2003; Safdar et al 2004). The PAE combined with the long t½ of daptomycin allows for once daily dosing in patients with normal renal function.

Daptomycin should not be used to treat pneumonia. This is due to the fact that daptomycin is inhibited by surfactant (Silverman et al 2005).

**Spectrum of activity**

As mentioned before, daptomycin has a broad spectrum of activity against gram-positive organisms, both aerobic and anaerobic. This includes resistant strains as well such as MRSA, GISA, VRE, CoNS, and PRSP. Calcium concentration of the media is an important factor in interpreting susceptibility testing (Fuchs et al 2000). The manufacturer recommends susceptibility testing with broth microdilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L (Cubicin package insert 2003). Below are the minimum inhibitory concentration of anti-infective needed to inhibit the growth of 90% of strains.
Daptomycin

(MIC<sub>90</sub>s) of a variety of gram-positive organisms from various in vitro studies:

- *Staphylococcus aureus*<sup>•</sup> MIC 0.5 mg/L (Streit et al. 2004) (*without a breakdown into MSSA and MRSA*).
- MSSA MIC 0.25 to 0.5 mg/L (Wise et al. 2001; Fuchs et al. 2002; Richter et al. 2003).
- MRSA MIC 0.5 to 1.0 mg/L (Wise et al. 2001; Fuchs et al. 2002; Richter et al. 2003).
- GISA MIC 0.125–0.5 mg/L (Akins and Rybak 2000, 2001). No differences were seen for susceptibility of vanA, vanB1, and vanD strains (Jevitt et al. 2003).
- VRSA: Daptomycin was found to be bactericidal against a VRSA (strain HMC3) isolated in Pennsylvania, US that was resistant to vancomycin through the presence of the vanA resistance gene; it also contained meca, erm( A), erm( B), tet( K) and aac(6′)-aph(2′), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides (Bozdogan et al. 2003).
- CoNS 0.5 mg/L (Wise et al. 2001; Fuchs et al. 2002; Sader et al. 2004; Streit et al. 2004).
- *Enterococcus fecalis*** MIC 1 to 2 mg/L (Wise et al. 2001; Richter et al. 2003; Streit et al. 2004) (**Enterococci were defined as vancomycin susceptible and those not further defined. If known to be VRE then stated as such**).
- Vancomycin-resistant *Enterococcus fecalis* MIC 1 to 4 mg/L (Richter et al. 2003; Sader et al. 2004).
- *Enterococcus faecium* MIC 2 to 4 mg/L (Wise et al. 2001; Richter et al. 2003; Streit et al. 2004).
- Vancomycin-resistant *Enterococcus faecium* MIC 2 to 4 mg/L (Richter et al. 2003; Sader et al. 2004).
- *Streptococcus pneumoniae* MIC 0.25 mg/L (Wise et al. 2001; Streit et al. 2004).
- PRSP MIC 0.25 mg/L (Sader et al. 2004).

Susceptibility breakpoints for as set forth by the Food and Drug Administration (FDA), which are the same as those from the National Committee for Clinical Laboratory Standards, are as follows (Cubicin package insert 2003; Streit et al. 2005):

- *Staphylococcus aureus* (MSSA and MRSA) <1 mg/L
- *Streptococcus spp.* (S. pyogenes, S. agalactiae, and S. dysgalactiae subsp. equisimilis) ≤ 1 mg/L
- *Enterococcus fecalis* (vancomycin-susceptible only) <4 mg/L

**Resistance**

There appears to be a low rate of spontaneous resistance to daptomycin with limited increases in MIC and relative ease of treatment of resistant isolates (Silverman et al. 2001).

Population analysis of three *Staphylococcus aureus* isolates for which the daptomycin MICs were 8 mg/mL showed a pattern of homogeneous resistance (Jevitt et al. 2003).

There have been multiple case reports of gram-positive organisms with daptomycin resistance, these include MRSA (Mangili et al. 2005), *Enterococcus faecium* (Sabol et al. 2005; Long et al. 2005), and *Enterococcus fecalis* (Munoz-Price et al. 2005).

**Adverse drug reactions**

Early in clinical trials daptomycin was found to have skeletal muscle effects that included myopathy with muscle weakness and elevated serum creatine phosphokinase (CPK). Further testing using a dog model revealed that this was more of a problem with fractioned dosing that could be overcome by changing the dosing schedule to once daily from every twelve hours (Oleson et al. 2000).
Daptomycin is generally well tolerated (Dvorchik et al. 2003; Arbeit et al. 2004). A large randomized trial evaluating the safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections (cSSSI) involving 1092 patients revealed the frequency, distribution, and severity of adverse events to be similar for daptomycin and standard therapy (Arbeit et al. 2004) (Table 1). There was a case report of significant myopathy with daptomycin without pronounced CPK elevation (CPK <500 U/L) at a dose of 6 mg/kg intravenously per day (Veligandla et al. 2004). There has also been a case report of myopathy and possible hepatotoxicity in a patient with underlying chronic liver disease, but the elevations in the transaminases were mild (aspartase aminotransferase 239 U/L and alanine aminotransferase 48 U/L) (Echevarria et al. 2005). It is recommended by the manufacturer that in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevation >1000 U/L, or in patients without reported symptoms who have marked elevation in CPK (≥10x ULN), daptomycin should be discontinued (Cubicin package insert 2003).

Clinical uses
Daptomycin is currently only approved for the treatment of cSSSI caused by susceptible Staphylococcus aureus (MSSA and MRSA), Streptococcus spp. (S. pyogenes, S. agalactiae, and S. dysgalactiae subsp. equisimilis), and Enterococcus faecalis (vancomycin-susceptible only) (Cubicin package insert 2003; Arbeit et al. 2004). This includes diabetic foot ulcers (Arbeit et al. 2004; Lipsky and Stoutenburgh 2005).

Drugs–drug interactions
Daptomycin is without any known significant drug–drug interactions. Nonetheless, the manufacturer recommends giving consideration to temporarily discontinuing use of HMG CoA reductase inhibitors while patients receive daptomycin (Cubicin package insert 2003). This is recommended due to the potential confusion that may arise if a patient on an HMG CoA reductase inhibitor were to experience myopathy or an increase in CPK level.
Daptomycin effective in the treatment of urinary tract infections due to such pathogens, but this warrants further studies. Daptomycin was at least equivalent to vancomycin against chronic foreign body infections due to Staphylococcus aureus, though vancomycin has poor activity in these infections. In a prospective study of daptomycin in the treatment of prosthetic joint infections, 5 of 7 patients with MRSA infections experienced treatment failures, so the efficacy of daptomycin in the treatment of prosthetic joint infections is uncertain (Rao and David 2005). Patients with moderate hepatic impairment receiving daptomycin do not require an adjustment in daptomycin dose or dose regimen (Dvorchik 2004). No adjustment in daptomycin dose or dose regimen should be required based solely on obesity (Dvorchik and Dapcho 2005). An international, multicenter, randomized open label trial using the off-label dose of daptomycin at 6 mg/kg every 24 hours showed that this dose was similar in efficacy to standard therapy for Staphylococcus aureus bacteremia and endocarditis (Fowler et al 2005).

### Dose

The dose of daptomycin is 4 mg/kg intravenously every 24 hours for patients with normal renal function (Cubicin package insert 2003; Arbeit et al 2004). For patients with a creatinine clearance of less than 30 mg/min, including those patients on hemodialysis, continuous ambulatory peritoneal dialysis, or continuous renal replacement therapy (CRRT) which includes continuous arteriovenous hemofiltration (CAVH), continuous venovenous hemofiltration (CVVH), continuous arteriovenous hemodialysis (CAVHD), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodialfiltration (CVVHDF), the dose is 4 mg/kg intravenously every 48 hours (Cubicin package insert 2003; Arbeit et al 2004; Trotman et al 2005). Patients with moderate hepatic impairment receiving daptomycin do not require an adjustment in daptomycin dose or dose regimen (Dvorchik 2004). No adjustment in daptomycin dose or dose regimen should be required based solely on obesity (Dvorchik and Dapcho 2005). An international, multicenter, randomized open label trial using the off-label dose of daptomycin at 6 mg/kg every 24 hours showed that this dose was similar in efficacy to standard therapy for Staphylococcus aureus bacteremia and endocarditis (Fowler et al 2005).

### Table 1

| Adverse event                      | n (%) of patients | Daptomycin group (n=534) | Comparator group* (n=558) |
|-----------------------------------|-------------------|--------------------------|----------------------------|
| Constipation                      | 33 (6.2)          | 38 (6.8)                 |                            |
| Nausea                            | 31 (5.8)          | 53 (9.5)                 |                            |
| Injection site reaction           | 31 (5.8)          | 43 (7.7)                 |                            |
| Headache                          | 29 (5.4)          | 30 (5.4)                 |                            |
| Diarrhea                          | 28 (5.2)          | 24 (4.3)                 |                            |
| Insomnia                          | 24 (4.5)          | 30 (5.4)                 |                            |
| Rash                              | 23 (4.3)          | 21 (3.8)                 |                            |
| Vomiting                          | 17 (3.2)          | 21 (3.8)                 |                            |
| Abnormal liver function test results| 16 (3.0)         | 9 (1.6)                  |                            |
| Pruritus                          | 15 (2.8)          | 21 (3.8)                 |                            |
| Elevated serum CPK level          | 15 (2.8)          | 10 (1.8)                 |                            |
| Fungal infection                  | 14 (2.6)          | 18 (3.2)                 |                            |
| Hypotension                       | 13 (2.4)          | 8 (1.4)                  |                            |
| Urinary tract infection           | 13 (2.4)          | 3 (0.5)                  |                            |
| Renal failure                     | 12 (2.2)          | 15 (2.7)                 |                            |
| Dizziness                         | 12 (2.2)          | 11 (2.0)                 |                            |
| Anemia                            | 11 (2.1)          | 13 (2.3)                 |                            |
| Dyspnea                           | 11 (2.1)          | 9 (1.6)                  |                            |
| Fever                             | 10 (1.9)          | 14 (2.5)                 |                            |
| Limb pain                         | 8 (1.5)           | 11 (2.0)                 |                            |
| Hypertension                      | 6 (1.1)           | 11 (2.0)                 |                            |
| Dyspepsia                         | 5 (0.9)           | 14 (2.5)                 |                            |
| Arthralgia                        | 5 (0.9)           | 12 (2.2)                 |                            |

**Note:** *Cloxacillin, flucloxacillin, nafcillin, oxacillin, or vancomycin.*

**Abbreviations:** CPK, creatine phosphokinase.

Copyright © 2004. Reproduced with permission from Arbeit RD, Maki D, Tally FP et al 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis, 38:1673–81.

### References

Akins RL, Rybak MJ. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother. 44:1925–9.

Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother, 45:454–9.

Alborn WE, Allen NE, Preston DA. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother, 35:2282–7.
Arbeit RD, Maki D, Tally FP, et al. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. *Clin Infect Dis*, 38:1673–81.

Bozdogan B, Esel D, Whitener C, et al. 2003. Antibacterial susceptibility of a vancomycin-resistant *Staphylococcus aureus* strain isolated at the Hershey Medical Center. *Antimicrob Chemother*, 52:864–8.

Cottagnoud P, Pfister M, Acosta F, et al. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. *Antimicrob Agents Chemother*, 48:3928–33.

Cubicin package insert. 2003. Lexington, MA: Cubist Pharmaceuticals Inc.

Dvorchik BH, Brazier D, DeBruin MF, et al. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. *Antimicrob Agents Chemother*, 47:1318–23.

Dvorchik B, Arbeit RD, Chung J, et al. 2004. Population pharmacokinetics of daptomycin. *Antimicrob Agents Chemother*, 48:2799–2807.

Dvorchik B. 2004. Moderate liver impairment has no influence on daptomycin pharmacokinetics. *J Clin Pharmacol*, 44:715–22.

Dvorchik DH, Dumphousse D. 2005. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. *J Clin Pharmacol*, 45:48–56.

Echevarria K, Datta P, Cadena J, et al. 2005. Severe myopathy and possible hepatotoxicity related to daptomycin. *J Antimicrob Chemother*, 55:599–600.

Fowler V, Cosgrove S, Abrutyn H, et al. 2005. Daptomycin vs. standard therapy for *Staphylococcus aureus* bacteremia and infective endocarditis [abstract]. 45th Annual International Conference of Antimicrobial Agents and Chemotherapy, 16–19 December, Washington, DC, USA. K-426a-2005

Fuchs PC, Barry AL, Brown SD. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. *Diagn Microbiol Infect Dis*, 38:51–8.

Fuchs PC, Barry AL, Brown SD. 2002. In vitro bactericidal activity of daptomycin against *Staphylococcus* and *Enterococcus* species. *Antimicrob Chemother*, 47:467–70.

Haworth CS, Sobieski MW, Scheld WM, et al. 1990. *Staphylococcus aureus* ventriculitis treated with single-dose intraventricular cefazolin and vancomycin in an in vitro peritoneal dialysate model. *Antimicrob Agents Chemother*, 34:245–51.

Hermens ED, Hovde LB, Hoteckiss JR, et al. 2003. Increased killing of *Staphylococcus* and *Streptococcus* by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. *Antimicrob Agents Chemother*, 47:3764–7.

Jeavitt LA, Smith AJ, Williams PP, et al. 2003. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of *Staphylococcus aureus* and *Enterococcus faecalis*. *Antimicrob Chemother*, 52:123–7.

Jevitt LA, Smith AJ, Williams PP, et al. 2004. In vitro activities of daptomycin, high-level penicillin- and quinolone-resistant pneumococci in experimental meningitis. *Antimicrob Agents Chemother*, 48:3928–33.

Kubin package insert. 2003. Lexington, MA: Cubist Pharmaceuticals Inc.

Levine DP, Lamp KC. 2005. Endocarditis treated with daptomycin; Experience from a registry [abstract]. 43rd IJDIAs abstracts, Infectious Diseases Society of America, 6–9 October, San Francisco, CA, USA. 359, p 99.

Lipsky BA, Stoutenburgh U. 2005. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. *J Antimicrob Chemother*, 55:240–5.

Long JK, Choueiri TK, Hall GS, et al. 2005. Daptomycin-resistant *Enterococcus faecium* in a patient with acute myeloid leukemia. *Mayo Clinic Proceedings*, 80:1215–16.

Mangili A, Bica I, Snyderman DR et al. 2005. Daptomycin-resistant, methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin Infect Dis*, 40:1058–0.

Mohan SS, McDermott BP, and Cunha BA. 2005. Methicillin-resistant *Staphylococcus aureus* prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. *Heart Lung*, 34:69–71.

Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant *Enterococcus faecalis* infection. *Clin Infect Dis*, 41:565–6.

Naber KG, Eisenstein BI, Tally FP. 2004. Daptomycin versus cirupirofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. *Infect Dis Clin Pract*, 12:322–7.

Oleson FB, Berman CL, Kirkpatrick JB, et al. 2000. Once-daily dosing in dogs optimizes daptomycin safety. *Antimicrob Agents Chemother*, 44:2948–53.

Pankuch GA, Jacobs MR, Appelbaum PC. 2003. Postantibiotic effects of daptomycin against 14 *staphylococcal* and *pneumococcal* clinical isolates. *Antimicrob Agents Chemother*, 47:3012–14.

Rao N, David R. 2005. A prospective study evaluating the efficacy of for the treatment of prosthetic joint infections [abstract]. 43rd IDSA abstracts, Infectious Diseases Society of America, 6–9 October, San Francisco, CA, USA. 388, p 105.

Richter SS, Kealey DE, Murray CT, et al. 2003. The in vitro activity of daptomycin against *Staphylococcus aureus* and *Enterococcus* species. *J Antimicrob Chemother*, 52:123–7.

Sabol K, Patterson JE, Lewis JS, et al. 2005. Emergence of daptomycin resistance in *Enterococcus faecium* during daptomycin therapy. *Antimicrob Agents Chemother*, 49:1664–5.

Sader HS, Streit JM, Fritsche TR, et al. 2004. Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. *Diagn Microbiol Infect Dis*, 50:201–4.

Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. *Antimicrob Agents Chemother*, 48:36–8.

Silverman JA, Oliver N, Andrew T, et al. 2001. Resistance studies with daptomycin. *Antimicrob Agents Chemother*, 45:1799–1802.

Silverman JA, Martin LI, Vanpraagh ADG, et al. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. *J Infect Dis*, 191:2149–52.

Steinbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J Antimicrob Chemother*, 55:283–8.

Streit JM, Jones RN, Sader HS. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. *J Antimicrob Chemother*, 53:669–74.

Streit JM, Steinbergen JN, Thorne GM, et al. 2005. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and *Streptococcus bovis*. *J Antimicrob Chemother*, 55:574–8.

Tally FP, DeBruin MF. 2000. Development of daptomycin for Gram-positive infections. *J Antimicrob Chemother*, 46:523–6.

Trotman RL, Williamson JC, Shoemaker DM, et al. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. *Clin Infect Dis*, 41:1159–66.

Velgandla SR, Louie KR, Malesker MA, et al. 2004. Muscle pain associated with daptomycin. *Ann Pharmacother*, 38:1860–2.

Wise R, Andrews JM, Ashby JP. 2001. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. *J Antimicrob Chemother*, 48:563–7.

Woodworth JR, Nyhart EH, Brier GL, et al. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. *Antimicrob Agents Chemother*, 36:318–25.